Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173624
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Arias Barquet, Lluís | - |
dc.contributor.author | Monés, Jordi | - |
dc.date.accessioned | 2021-02-03T14:53:31Z | - |
dc.date.available | 2021-02-03T14:53:31Z | - |
dc.date.issued | 2010-02-01 | - |
dc.identifier.issn | 1177-5467 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173624 | - |
dc.description.abstract | Purpose: to determine the efficacy and safety of treating predominantly hemorrhagic age-related macular degeneration (AMD) with transconjunctival sutureless vitrectomy (TSV), tissue plasminogen activator (tPA), sulphur hexafluoride (SF6), and intravitreal bevacizumab. Methods: retrospective study, consecutive case series. Patients with acute hemorrhagic AMD treated with 25- or 23-gauge TSV, subretinal or intravitreal tPA, fluid-air-SF6 exchange and intravitreal injection of bevacizumab. All operations were performed within the first 5 days after the start of symptoms, which consisted of visual acuity (VA) loss and central scotoma. Results: fifteen eyes from 15 patients were included. The patients' mean age was 79.6 years, and the mean follow-up was 11.8 months. Five patients (33%) were receiving oral anticoagulant treatment. At baseline, the mean VA (logMAR values) was 1.5 (20/640 Snellen equivalent). At the last follow-up visit, the mean VA was 1.1 (20/250) (P < 0.0001; paired t-test). The submacular hemorrhage was successfully displaced in all the cases. Complications consisted of three cases of vitreous hemorrhage and a tear or the retinal pigment epithelium. Twelve cases (80%) did not require further treatment during the follow-up period. Conclusion: a surgical approach with 25- or 23-gauge TSV, tPA, SF6 and intravitreal bevacizumab is an efficacious and safe procedure in patients with hemorrhagic AMD. Early treatment is advisable for obtaining the optimal outcome. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Medical Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2147/opth.s8635 | - |
dc.relation.ispartof | Clinical Ophthalmology, 2010, vol. 18, num. 4, p. 67-72 | - |
dc.relation.uri | https://doi.org/10.2147/opth.s8635 | - |
dc.rights | cc-by-nc (c) Arias Barquet, Lluís et al., 2010 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Degeneració | - |
dc.subject.classification | Activador del plasminogen | - |
dc.subject.classification | Vitrectomia | - |
dc.subject.other | Degeneration | - |
dc.subject.other | Plasminogen activators | - |
dc.subject.other | Vitrectomy | - |
dc.title | Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 678960 | - |
dc.date.updated | 2021-02-03T14:53:31Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 20186279 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
678960.pdf | 2.17 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License